CBT for Insomnia: Why Sleep Medication Is Not the First Answer
CBT for insomnia (CBT-I) is recommended by NICE as the first-line treatment for chronic insomnia in adults, ahead of pharmacological treatment. This reflects a body of evidence showing that CBT-I produces outcomes at least equivalent to sleep medication in the short term and substantially better in the long term, with effects that persist and often continue to improve after treatment has ended. Sleep medication works by suppressing the systems involved in wakefulness; CBT-I works by addressing the mechanisms that maintain the insomnia — a fundamentally different intervention whose effects are more durable.
The theoretical model underlying CBT-I is Arthur Spielman's 3P framework. Predisposing factors are the trait characteristics that increase vulnerability to insomnia: elevated physiological arousal, anxiety trait, a tendency to ruminate. Precipitating factors are the events that trigger an acute episode: stress, illness, grief, significant life change. Most people experience occasional acute insomnia in response to stressors; it resolves when the stressor resolves. In chronic insomnia, the acute episode persists beyond the precipitating event because perpetuating factors have taken hold.
The perpetuating factors are the behaviours and cognitions that maintain insomnia long after the original trigger has passed. Spending excessive time in bed to compensate for poor sleep reduces homeostatic sleep drive (the biological pressure to sleep that accumulates during waking hours) and fragments sleep further. Irregular sleep and wake times disrupt the circadian rhythm. Daytime napping reduces night-time sleep drive. Using the bed for wakeful activities — watching screens, working, lying awake worrying — extinguishes the association between bed and sleep that the sleeping brain relies on. And catastrophic beliefs about sleep — "I need eight hours to function", "I will never sleep well again", "something is medically wrong" — generate the hyperarousal that prevents the physiological state necessary for sleep onset.
Sleep restriction therapy, the most active and initially counterintuitive component of CBT-I, involves limiting time in bed to approximately match the current actual sleep time — typically six or six and a half hours even for someone spending nine hours in bed. This creates a period of mild sleep deprivation that dramatically increases homeostatic sleep drive, consolidates the fragmented sleep, and restores the sleep-wake architecture. As sleep consolidates, time in bed is gradually extended. Stimulus control re-establishes the association between bed and sleep by making the bedroom environment and bedtime reliably predictive of sleep rather than of wakefulness and anxiety. Combined with cognitive restructuring of the beliefs that maintain hyperarousal, these components produce the durable change that medication alone cannot.
Digital CBT-I has substantially increased the accessibility of evidence-based insomnia treatment. Sleepio, the digital CBT-I programme developed from the work of Colin Espie at Oxford, has demonstrated efficacy in multiple RCTs and is available on NHS prescription in some areas; Somryst is cleared by the FDA as a prescription digital therapeutic for insomnia and has demonstrated efficacy. These digital programmes deliver the full CBT-I protocol without requiring a therapist, broadening access to a population for whom face-to-face therapy is unavailable or impractical. Sleep hygiene alone — the recommendations about caffeine, screen exposure, room temperature, and consistent bedtimes — has weak evidence when implemented in isolation; it is the sleep restriction and stimulus control components that do most of the therapeutic work. Maia, the AI companion in Asclepiad, offers space for understanding what maintains chronic insomnia and what the evidence-based approaches involve.
Frequently Asked Questions
Is Asclepiad designed for insomnia?
Asclepiad is well-suited to understanding CBT-I — the 3P model, the perpetuating factors that maintain insomnia, and what the evidence-based components involve. For structured treatment: GP referral or self-referral to NHS IAPT (nhs.uk/mental-health/talking-therapies-medicine-treatments) provides access to CBT-I; Sleepio (sleepio.com) offers digital CBT-I; the Society of Behavioural Sleep Medicine (behavioralsleep.org) lists specialist practitioners.